上调全年业绩指引!药明康德告诉你:在动荡时代,稳定与可靠有多宝贵

地产k线
29 Jul

2025年已过大半,尽管创新药领域重磅合作频现,但全球医疗健康投融资依然处于低位,行业全面恢复尚需时日。在此背景下,药明康德(603259.SH/2359.HK)于7月28日晚间发布了2025年中期报告:上半年持续经营业务收入达204.2亿元,同比增长24.2%;经调整non-IFRS归母净利润63.1亿元,同比增长44.4%。尤为值得关注的是,公司宣布上调全年业绩指引,预计持续经营业务收入增速由...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10